Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...

Advertisements International Myeloma Foundation (IMF) to Hold Miracles for Myeloma Virtual/In-Person 5K Run/Walk in Boca Raton, FL Advertisements Boca Raton, FL – This March, in honor of Myeloma ...

The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last obstacle in front of the launch of the drug in Italy, which is now scheduled ...

one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with multiple myeloma. The double-headed antibody binds to CD3 on T cells and redirects them to BCMA ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the ...